US20030013170A1 - Inhibitors of receptor activator of NF-kappaB and uses thereof - Google Patents
Inhibitors of receptor activator of NF-kappaB and uses thereof Download PDFInfo
- Publication number
- US20030013170A1 US20030013170A1 US10/143,293 US14329302A US2003013170A1 US 20030013170 A1 US20030013170 A1 US 20030013170A1 US 14329302 A US14329302 A US 14329302A US 2003013170 A1 US2003013170 A1 US 2003013170A1
- Authority
- US
- United States
- Prior art keywords
- traf6
- polypeptide
- group
- receptor activator
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000010498 Receptor Activator of Nuclear Factor-kappa B Human genes 0.000 title claims abstract description 73
- 108010038036 Receptor Activator of Nuclear Factor-kappa B Proteins 0.000 title claims abstract description 73
- 239000003112 inhibitor Substances 0.000 title abstract description 8
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 claims abstract description 118
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 claims abstract description 118
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 116
- 210000002997 osteoclast Anatomy 0.000 claims abstract description 72
- 108010025832 RANK Ligand Proteins 0.000 claims abstract description 69
- 230000027455 binding Effects 0.000 claims abstract description 64
- 230000004069 differentiation Effects 0.000 claims abstract description 45
- 230000001404 mediated effect Effects 0.000 claims abstract description 28
- 230000003993 interaction Effects 0.000 claims abstract description 24
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 15
- 208000029725 Metabolic bone disease Diseases 0.000 claims abstract description 8
- 206010003246 arthritis Diseases 0.000 claims abstract description 6
- 208000032839 leukemia Diseases 0.000 claims abstract description 6
- 208000037819 metastatic cancer Diseases 0.000 claims abstract description 6
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 97
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 claims description 71
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 70
- 229920001184 polypeptide Polymers 0.000 claims description 42
- 239000003446 ligand Substances 0.000 claims description 24
- 206010006187 Breast cancer Diseases 0.000 claims description 23
- 208000026310 Breast neoplasm Diseases 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 230000011664 signaling Effects 0.000 claims description 22
- 241000282414 Homo sapiens Species 0.000 claims description 21
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 16
- 230000005764 inhibitory process Effects 0.000 claims description 16
- 235000018102 proteins Nutrition 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 235000009697 arginine Nutrition 0.000 claims description 12
- 108700039861 Human immunodeficiency virus 1 tat peptide (48-60) Proteins 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 150000001484 arginines Chemical class 0.000 claims description 9
- 101150013553 CD40 gene Proteins 0.000 claims description 8
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 claims description 6
- 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 claims description 6
- 102000040945 Transcription factor Human genes 0.000 claims description 6
- 108091023040 Transcription factor Proteins 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 230000004568 DNA-binding Effects 0.000 claims description 5
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 5
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 5
- 101001109137 Homo sapiens Receptor-interacting serine/threonine-protein kinase 2 Proteins 0.000 claims description 5
- 101710199012 Interleukin-1 receptor-associated kinase 3 Proteins 0.000 claims description 5
- 102100023530 Interleukin-1 receptor-associated kinase 3 Human genes 0.000 claims description 5
- 230000004570 RNA-binding Effects 0.000 claims description 5
- 108020000999 Viral RNA Proteins 0.000 claims description 5
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 claims description 4
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 claims description 4
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 claims description 3
- 241000724256 Brome mosaic virus Species 0.000 claims description 3
- 101710132601 Capsid protein Proteins 0.000 claims description 3
- 101710094648 Coat protein Proteins 0.000 claims description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 claims description 3
- 241000723754 Flock house virus Species 0.000 claims description 3
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 3
- 101000733257 Homo sapiens Rho guanine nucleotide exchange factor 28 Proteins 0.000 claims description 3
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 claims description 3
- 108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 claims description 3
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 claims description 3
- 101710125418 Major capsid protein Proteins 0.000 claims description 3
- 101710141454 Nucleoprotein Proteins 0.000 claims description 3
- 101710083689 Probable capsid protein Proteins 0.000 claims description 3
- 102100033204 Rho guanine nucleotide exchange factor 28 Human genes 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 claims description 3
- 102100023132 Transcription factor Jun Human genes 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000020395 negative regulation of osteoclast differentiation Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 108010011110 polyarginine Proteins 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 2
- 238000001476 gene delivery Methods 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 102000014128 RANK Ligand Human genes 0.000 abstract 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 18
- 102000003945 NF-kappa B Human genes 0.000 description 17
- 230000004913 activation Effects 0.000 description 17
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 17
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 15
- 102000004393 TNF receptor-associated factor 2 Human genes 0.000 description 15
- 108010057466 NF-kappa B Proteins 0.000 description 14
- 102000008108 Osteoprotegerin Human genes 0.000 description 14
- 108010035042 Osteoprotegerin Proteins 0.000 description 14
- 102000003718 TNF receptor-associated factor 5 Human genes 0.000 description 14
- 108090000001 TNF receptor-associated factor 5 Proteins 0.000 description 14
- 230000001086 cytosolic effect Effects 0.000 description 14
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 14
- 239000012528 membrane Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 9
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 9
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 241001529936 Murinae Species 0.000 description 5
- 102000004398 TNF receptor-associated factor 1 Human genes 0.000 description 5
- 108090000920 TNF receptor-associated factor 1 Proteins 0.000 description 5
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 5
- 208000006386 Bone Resorption Diseases 0.000 description 4
- 206010005949 Bone cancer Diseases 0.000 description 4
- 208000020084 Bone disease Diseases 0.000 description 4
- 208000018084 Bone neoplasm Diseases 0.000 description 4
- 101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 4
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 4
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 4
- 108010014632 NF-kappa B kinase Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- UPJGUQPLYWTISV-GUBZILKMSA-N Pro-Gln-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UPJGUQPLYWTISV-GUBZILKMSA-N 0.000 description 4
- FTVRVZNYIYWJGB-ACZMJKKPSA-N Ser-Asp-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FTVRVZNYIYWJGB-ACZMJKKPSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 102000000160 Tumor Necrosis Factor Receptor-Associated Peptides and Proteins Human genes 0.000 description 4
- 108010080432 Tumor Necrosis Factor Receptor-Associated Peptides and Proteins Proteins 0.000 description 4
- 101710097161 Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 4
- 102000035181 adaptor proteins Human genes 0.000 description 4
- 108091005764 adaptor proteins Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 108010008237 glutamyl-valyl-glycine Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 101000852483 Homo sapiens Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 3
- 101000648503 Homo sapiens Tumor necrosis factor receptor superfamily member 11A Proteins 0.000 description 3
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 3
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 3
- 101710182491 Interleukin-1 receptor-associated kinase-like 2 Proteins 0.000 description 3
- 102100036433 Interleukin-1 receptor-associated kinase-like 2 Human genes 0.000 description 3
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 3
- 206010027452 Metastases to bone Diseases 0.000 description 3
- 101000852257 Mus musculus Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 3
- 101100046557 Mus musculus Tnfrsf11a gene Proteins 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- FRKBNXCFJBPJOL-GUBZILKMSA-N Pro-Glu-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FRKBNXCFJBPJOL-GUBZILKMSA-N 0.000 description 3
- IURWWZYKYPEANQ-HJGDQZAQSA-N Pro-Thr-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IURWWZYKYPEANQ-HJGDQZAQSA-N 0.000 description 3
- IMNVAOPEMFDAQD-NHCYSSNCSA-N Pro-Val-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IMNVAOPEMFDAQD-NHCYSSNCSA-N 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 210000000069 breast epithelial cell Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000011198 co-culture assay Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000000021 kinase assay Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 210000001721 multinucleated osteoclast Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- XVZCXCTYGHPNEM-IHRRRGAJSA-N (2s)-1-[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O XVZCXCTYGHPNEM-IHRRRGAJSA-N 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
- 102000013563 Acid Phosphatase Human genes 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- ATABBWFGOHKROJ-GUBZILKMSA-N Arg-Pro-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O ATABBWFGOHKROJ-GUBZILKMSA-N 0.000 description 2
- MYTHOBCLNIOFBL-SRVKXCTJSA-N Asn-Ser-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MYTHOBCLNIOFBL-SRVKXCTJSA-N 0.000 description 2
- RRKCPMGSRIDLNC-AVGNSLFASA-N Asp-Glu-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RRKCPMGSRIDLNC-AVGNSLFASA-N 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- VNTGPISAOMAXRK-CIUDSAMLSA-N Gln-Pro-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O VNTGPISAOMAXRK-CIUDSAMLSA-N 0.000 description 2
- YKLNMGJYMNPBCP-ACZMJKKPSA-N Glu-Asn-Asp Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YKLNMGJYMNPBCP-ACZMJKKPSA-N 0.000 description 2
- XXCDTYBVGMPIOA-FXQIFTODSA-N Glu-Asp-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XXCDTYBVGMPIOA-FXQIFTODSA-N 0.000 description 2
- SYWCGQOIIARSIX-SRVKXCTJSA-N Glu-Pro-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O SYWCGQOIIARSIX-SRVKXCTJSA-N 0.000 description 2
- HQTDNEZTGZUWSY-XVKPBYJWSA-N Glu-Val-Gly Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)NCC(O)=O HQTDNEZTGZUWSY-XVKPBYJWSA-N 0.000 description 2
- 101000852255 Homo sapiens Interleukin-1 receptor-associated kinase-like 2 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- KTNGVMMGIQWIDV-OSUNSFLBSA-N Ile-Pro-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O KTNGVMMGIQWIDV-OSUNSFLBSA-N 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 102000019148 NF-kappaB-inducing kinase activity proteins Human genes 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 2
- 208000003076 Osteolysis Diseases 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- INXAPZFIOVGHSV-CIUDSAMLSA-N Pro-Asn-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1 INXAPZFIOVGHSV-CIUDSAMLSA-N 0.000 description 2
- VYWNORHENYEQDW-YUMQZZPRSA-N Pro-Gly-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 VYWNORHENYEQDW-YUMQZZPRSA-N 0.000 description 2
- HFNPOYOKIPGAEI-SRVKXCTJSA-N Pro-Leu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 HFNPOYOKIPGAEI-SRVKXCTJSA-N 0.000 description 2
- MLKVIVZCFYRTIR-KKUMJFAQSA-N Pro-Phe-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O MLKVIVZCFYRTIR-KKUMJFAQSA-N 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- -1 RANK Proteins 0.000 description 2
- 102000001332 SRC Human genes 0.000 description 2
- 108060006706 SRC Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 102000008889 TNF receptor-associated factor TRAF Human genes 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- UUBKSZNKJUJQEJ-JRQIVUDYSA-N Tyr-Thr-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O UUBKSZNKJUJQEJ-JRQIVUDYSA-N 0.000 description 2
- WFENBJPLZMPVAX-XVKPBYJWSA-N Val-Gly-Glu Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O WFENBJPLZMPVAX-XVKPBYJWSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 102000053530 human TNFRSF11A Human genes 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 208000002865 osteopetrosis Diseases 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010379 pull-down assay Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GHNDBBVSWOWYII-LPEHRKFASA-N Arg-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O GHNDBBVSWOWYII-LPEHRKFASA-N 0.000 description 1
- PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
- JUWQNWXEGDYCIE-YUMQZZPRSA-N Arg-Gln-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O JUWQNWXEGDYCIE-YUMQZZPRSA-N 0.000 description 1
- BJNUAWGXPSHQMJ-DCAQKATOSA-N Arg-Gln-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O BJNUAWGXPSHQMJ-DCAQKATOSA-N 0.000 description 1
- BNYNOWJESJJIOI-XUXIUFHCSA-N Arg-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N BNYNOWJESJJIOI-XUXIUFHCSA-N 0.000 description 1
- OPEPUCYIGFEGSW-WDSKDSINSA-N Asn-Gly-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OPEPUCYIGFEGSW-WDSKDSINSA-N 0.000 description 1
- NSTBNYOKCZKOMI-AVGNSLFASA-N Asn-Tyr-Glu Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O NSTBNYOKCZKOMI-AVGNSLFASA-N 0.000 description 1
- WCFCYFDBMNFSPA-ACZMJKKPSA-N Asp-Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O WCFCYFDBMNFSPA-ACZMJKKPSA-N 0.000 description 1
- UWOPETAWXDZUJR-ACZMJKKPSA-N Asp-Cys-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O UWOPETAWXDZUJR-ACZMJKKPSA-N 0.000 description 1
- CRNKLABLTICXDV-GUBZILKMSA-N Asp-His-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N CRNKLABLTICXDV-GUBZILKMSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- NLCZGISONIGRQP-DCAQKATOSA-N Cys-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N NLCZGISONIGRQP-DCAQKATOSA-N 0.000 description 1
- ODDOYXKAHLKKQY-MMWGEVLESA-N Cys-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N ODDOYXKAHLKKQY-MMWGEVLESA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108091006010 FLAG-tagged proteins Proteins 0.000 description 1
- 208000023981 Familial expansile osteolysis Diseases 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- FMNHBTKMRFVGRO-FOHZUACHSA-N Gly-Asn-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CN FMNHBTKMRFVGRO-FOHZUACHSA-N 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 description 1
- 101000977768 Homo sapiens Interleukin-1 receptor-associated kinase 3 Proteins 0.000 description 1
- 101000889795 Homo sapiens Rabankyrin-5 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- ZZHGKECPZXPXJF-PCBIJLKTSA-N Ile-Asn-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZZHGKECPZXPXJF-PCBIJLKTSA-N 0.000 description 1
- HODVZHLJUUWPKY-STECZYCISA-N Ile-Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)CC)CC1=CC=C(O)C=C1 HODVZHLJUUWPKY-STECZYCISA-N 0.000 description 1
- 108010056372 L-T6DP-1 peptide Proteins 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- HWMZUBUEOYAQSC-DCAQKATOSA-N Lys-Gln-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O HWMZUBUEOYAQSC-DCAQKATOSA-N 0.000 description 1
- 102000002569 MAP Kinase Kinase 4 Human genes 0.000 description 1
- 108010068304 MAP Kinase Kinase 4 Proteins 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- MTBVQFFQMXHCPC-CIUDSAMLSA-N Met-Glu-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MTBVQFFQMXHCPC-CIUDSAMLSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 1
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- UNLYPPYNDXHGDG-IHRRRGAJSA-N Phe-Gln-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 UNLYPPYNDXHGDG-IHRRRGAJSA-N 0.000 description 1
- BONHGTUEEPIMPM-AVGNSLFASA-N Phe-Ser-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O BONHGTUEEPIMPM-AVGNSLFASA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- QSKCKTUQPICLSO-AVGNSLFASA-N Pro-Arg-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O QSKCKTUQPICLSO-AVGNSLFASA-N 0.000 description 1
- FKVNLUZHSFCNGY-RVMXOQNASA-N Pro-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 FKVNLUZHSFCNGY-RVMXOQNASA-N 0.000 description 1
- XYSXOCIWCPFOCG-IHRRRGAJSA-N Pro-Leu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XYSXOCIWCPFOCG-IHRRRGAJSA-N 0.000 description 1
- RFWXYTJSVDUBBZ-DCAQKATOSA-N Pro-Pro-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RFWXYTJSVDUBBZ-DCAQKATOSA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- ITUDDXVFGFEKPD-NAKRPEOUSA-N Pro-Ser-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ITUDDXVFGFEKPD-NAKRPEOUSA-N 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- UGJRQLURDVGULT-LKXGYXEUSA-N Ser-Asn-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UGJRQLURDVGULT-LKXGYXEUSA-N 0.000 description 1
- XWCYBVBLJRWOFR-WDSKDSINSA-N Ser-Gln-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O XWCYBVBLJRWOFR-WDSKDSINSA-N 0.000 description 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 102000004399 TNF receptor-associated factor 3 Human genes 0.000 description 1
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 description 1
- 102000003715 TNF receptor-associated factor 4 Human genes 0.000 description 1
- 108090000008 TNF receptor-associated factor 4 Proteins 0.000 description 1
- 108050000808 TNF receptor-associated factor TRAF Proteins 0.000 description 1
- 108091084544 TNF receptor-associated factor family Proteins 0.000 description 1
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 1
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 1
- YOSLMIPKOUAHKI-OLHMAJIHSA-N Thr-Asp-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O YOSLMIPKOUAHKI-OLHMAJIHSA-N 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102100028787 Tumor necrosis factor receptor superfamily member 11A Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000000787 affinity precipitation Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 201000011143 bone giant cell tumor Diseases 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 108010079413 glycyl-prolyl-glutamic acid Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000046801 human IRAK3 Human genes 0.000 description 1
- 102000057608 human RIPK2 Human genes 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000026749 regulation of bone remodeling Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Definitions
- the present invention relates generally to the fields of cytokine biology and bone diseases. More specifically, the present invention provides inhibitors of receptor activator of NF- ⁇ B (RANK) for therapy of disorders such as diseases associated with bone resorption.
- RANK receptor activator of NF- ⁇ B
- TNF and TNF receptor superfamilies play critical roles in the initiation and regulation of the immune response (1-3). Although members of these families share many overlapping biological functions, it appears from gene knockout studies that they have unique features.
- One such receptor/ligand pair receptor activator of NF- ⁇ B (RANK) and its ligand (RANKL/TRANCE/ODF/OPGL), is critically involved in regulation of bone remodeling and osteoclastogenesis (4).
- RANKL also functions in lymph node organogenesis and lymphocyte development (5).
- receptor activator of NF- ⁇ B and RANKL are implicated in the interactions between T cells and dendritic cells during the immune response (6).
- NF- ⁇ B nuclear factor- ⁇ B
- JNK c-Jun N-terminal kinase
- the TNF receptor-associated factor family consists of six distinct proteins, each of which possesses a C-terminal homologous domain that is critical for self-association and is required for interaction with the receptors. All of the TNF receptor-associated factors, except for TRAF1 and TRAF4, also contain ring and zinc finger motifs in their N-termini, which appear to be utilized for interacting with other signaling molecules. Similar to the trimeric structure of the ligands and receptors of the TNF family, the C-terminus of the TRAF2 adapts a trimeric structure, as reported for TRAF2 in its interaction with peptides derived from TNF receptor 1 and CD40 (15, 16). This trimeric structure of the TNF receptor-associated factor molecules likely enables them to associate with downstream adapter proteins.
- TRAF2, TRAF5, and TRAF6 interact with receptor activator of NF- ⁇ B (RANK) and that receptor activator of NF- ⁇ B could activate both the NF- ⁇ B and JNK pathways (7). Subsequently, a more detailed analysis of the interaction of these TNF receptor-associated factors with receptor activator of NF- ⁇ B was reported (8).
- a novel TRAF6-binding motif has been identified in RANK that is distinct from the TRAF2- and TRAF5-binding domains.
- a homologous TRAF6-binding motif in CD40 was described using a combinatorial peptide library approach (17).
- TRAF6 binding domain in RANK was sufficient for activation of NF- ⁇ B , suggesting that TRAF2 and TRAF5 are not necessary for NF- ⁇ B activation. However, it appears that the TRAF2-binding motif is sufficient for JNK activation, although the TRAF6-binding domain could also activate JNK, albeit to a lesser extent. Additionally, NIK (NF- ⁇ B inducing kinase) was also found to be required for the activation of NF- ⁇ B by receptor activator of NF- ⁇ B. In addition to TRAF2, TRAF5, and TRAF6, it has been demonstrated that TRAF1 and TRAF3 also associate with the carboxy terminus of receptor activator of NF- ⁇ B (9-12).
- TRAF2, TRAF5, and TRAF6 have been used to evaluate their role in NF- ⁇ B activation by RANK. It appears that all of the dominant negative TRAFs differentially inhibit the activation of NF- ⁇ B induced b y overexpression of RANK in 293 cells (9, 12). However, inclusion of all dominant negative mutants of TRAF2, TRAF5, and TRAF6 did not completely eliminate the activation of NF- ⁇ B induced by RANK in 293 cells (12).
- Stimulation of RANK also caused the recruitment of TRAF6, which in turn recruits and activates c-Src, which appears to be responsible for activation of phosphoinositol-3-kinase and protein kinase B/AKT, a molecule potentially involved in cell survival (18).
- TRAF6 appears to be essential for osteoclast differentiation as indicated in mice lacking TRAF6.
- t h e interaction of receptor activator of NF- ⁇ B with TRAF6 may be a unique target for therapeutic intervention, and the ability to disrupt this interaction by a competitive, cell permeable peptide remains to be investigated.
- the prior art is deficient in methods of disrupting the interaction between receptor activator of NF- ⁇ B and TRAF6 in order to inhibit RANKL signaling and osteoclast differentiation induced by RANKL.
- Such inhibitors would be useful as therapeutics in bone disorders and cancer associated with increased bone resorption.
- the present invention fulfills this long-standing need and desire in the art.
- TRAF6 (TNF receptor-associated factor 6) is a critical adapter protein for Receptor Activator of NF- ⁇ B (RANK) signaling.
- the present invention discloses a novel TRAF6 decoy peptide (T6DP) with and without a peptide leader sequence that allows for transversing the cellular membrane.
- T6DP novel TRAF6 decoy peptide
- Evidence disclosed herein indicate that the TRAF6 decoy peptide inhibits early events associated with RANKL signaling and RANKL-mediated osteoclast differentiation only when the leader sequence is attached. This data indicates that targeted disruption of interaction between Receptor Activator of NF- ⁇ B and TRAF6 may prove useful as a therapeutic for metabolic bone disorders, leukemia, arthritis, and metastatic cancer of the bone.
- the present invention provides polypeptides that inhibit signaling mediated by TNF receptor-associated factor 6 (TRAF6), wherein the polypeptides comprise of a TRAF6 binding domain and a leader signal sequence.
- TNF receptor-associated factor 6 TNF receptor-associated factor 6
- the present invention is further drawn to methods of inhibiting Receptor Activator of NF- ⁇ B Ligand (RANKL)-induced osteoclast differentiation using the polypeptides disclosed herein.
- a non-peptide analog that mimics the function of the polypeptide disclosed herein, wherein said non-peptide analog inhibits signaling mediated by TRAF6.
- the present invention is further drawn to methods of inhibiting Receptor Activator of NF- ⁇ B Ligand (RANKL)-induced osteoclast differentiation using a non-peptide analog that mimics the function of the polypeptide disclosed herein.
- RTKL Receptor Activator of NF- ⁇ B Ligand
- FIG. 1 shows the novel TRAF6 binding domain in RANK.
- FIG. 1A shows the consensus sequence of the TRAF6 binding domain. The region within the amino acid sequence of CD40 (residues 230-245) that specifically interacts with TRAF6 (38) was used as the template for alignment of RANK, IRAK1, and IRAK2. Identical residues are in bold. A consensus motif is shown on the bottom.
- FIG. 1B shows the peptides used in the present study.
- the hydrophobic domain of Kaposi fibroblast growth factor signal sequence (underlined) (36) was attached to the two potential TRAF6 binding domains from murine receptor activator of NF- ⁇ B. Additionally, two peptides lacking the leader sequence were synthesized.
- FIG. 2 shows L-T6Bp-1 inhibits RANKL-mediated osteoclast differentiation in RAW264.7 cells.
- FIG. 2A shows RANKL-induces TRAP positive osteoclasts.
- RAW264.7 cells were plated in 12-well plates and stimulated with RANKL (30 ng/ml) for 4 days. Cells were stained for TRAP essentially as described below. Photographs were taken using a 10 ⁇ objective lens.
- FIG. 2B shows L-T6DP-1 inhibits osteoclast differentiation.
- RAW cells were plated as described in FIG. 2A and treated with RANKL in the presence of 1, 30, or 100 ⁇ M of peptides as indicated. On day 4 cells were stained and evaluated as in FIG. 2A.
- FIG. 2C shows L-T6DP-1 inhibits the total number of TRAP positive osteoclasts induced by RANKL.
- RAW264.7 cells were plated in 48-well plates in triplicate and treated with RANKL in the presence of increasing amounts of the indicated peptides. After 4-5 days, the cells were stained for TRAP and the total numbers of osteoclasts were counted as described below.
- FIG. 3 shows leader TRAF6-binding peptide inhibits normal mouse derived osteoclast differentiation by RANKL and M-CSF.
- FIG. 3A shows mouse-derived monocytes were plated in 48-well plates in triplicate and costimulated with murine M-CSF (10 ng/ml) and RANKL(30 ng/ml) in the absence (0) or presence of the indicated peptides. After 6-7 days, the cells were fixed and stained for TRAP. The numbers of multi-nucleated, TRAP positive osteoclasts were counted.
- FIG. 3B shows LT6DP-1 inhibits osteoclast differentiation of mouse-derived monocytes.
- Mouse-derived monocytes were plated in 48-well plates and costimulated as in FIG. 3A with murine M-CSF (10 ng/ml) and RANKL (30 ng/ml) in the absence (left panel) or presence of the indicated peptides. After 6-7 days, the cells were fixed and stained for TRAP. A representative field from each well was taken at a magnification of 10 ⁇ .
- FIG. 4 shows that L-T6DP-1 specifically inhibits RANKL-induced NF- ⁇ B activation and TRAF6 binding.
- FIG. 4A shows inhibition of RANKL-mediated NF- ⁇ B activation by L-T6Bp-1.
- RAW264.7 cells were plated in 6-well plates and treated with the indicated peptides for 5 h, then treated with RANKL (10 nM) for 15 min.
- Nuclear and cytoplasmic extracts were prepared and a gel mobility shift assays was performed with 8 ⁇ g of nuclear extracts as described below.
- FIG. 4B shows inhibition of I ⁇ B degradation by L-T6DP-1.
- Cytoplasmic extracts (30 ⁇ g) from FIG. 4A were immunoblotted with anti-I ⁇ B as described below.
- FIG. 4C shows L-T6DP-1 inhibits TRAF6 from binding to the receptor activator of NF- ⁇ B cytoplasmic domain.
- Cellular extracts from human 293 cells transfected with either FLAG-TRAF2, -TRAF5, or -TRAF6 were mixed with GST or GST-RANKcd in the absence or presence of 100 ⁇ M of the indicated peptides.
- a GST-pull down assay was performed as described below. The bound TRAFs were visualized by immunoblotting with anti-FLAG antibodies.
- FIG. 5 shows L-T6DP-1 specifically inhibits RANKL-induced JNK, ERK, and p38 kinase activation.
- FIG. 5A shows inhibition of RANKL-mediated JNK activation by L-T6DP-1.
- RAW264.7 cells were plated in 6-well plates and treated with the indicated peptides for 6 h, then treated with RANKL (10 nM) for 1 5 min.
- Whole cell extracts were prepared and 30 ⁇ g of cell lysate was immunoprecipitated with anti-JNK1.
- In vitro kinase assays were performed using GST-Jun (1-79) as the substrate as described below.
- FIG. 5B and FIG. 5C show inhibition of RANKL-mediated ERK and p38 activation by L-T6DP-1.
- Whole cell extracts (30 ⁇ g) from FIG. 5A were separated by 10% SDS-PAGE and electroblotted onto a nitrocellulose membrane. The membranes were first immunoblotted with the indicated phospho-specific antibody and then stripped and re-probed with the indicated antibodies as described below.
- FIG. 6 shows L-T6DP-1 inhibits osteoclast differentiation induced by breast cancer cells.
- FIG. 6A Breast cancer cells (500/well) were plated in 24-well plates in the absence or presence of RAW cells (10000/well) and in the absence or presence of L-T6DP-1 or T6DP-1 (100 ⁇ M). After 5 days, the cells were fixed, stained for TRAP, and photographed with a 10 ⁇ objective lens.
- FIG. 6B shows RAW cells were cultured alone or in the presence of the indicated cells on synthetic bone slides (BD BiCoat Osteologic MultiTest Slides). After 6 days, the cells were removed b y washing the slide in bleach for 5 minutes and then washing thoroughly with distilled water. The slide was air dried and then photographs were taken with a light microscope (10 ⁇ objective lens). The ghosts of osteoclasts (arrow) can be seen where functional osteoclasts destroyed the synthetic bone matrix.
- FIG. 6C shows normal breast epithelial cells (MCF10A, 1000/well) grown in the presence of RAW and stained for TRAP as indicted in FIG. 6A.
- the right panel includes the addition of RANKL (100 ng/ml) to the co-culture.
- Receptor activator of NF- ⁇ B (RANK), a recently described member of the TNF receptor superfamily, is expressed primarily b y dendritic cells, osteoclast progenitors, activated B and T cells and osteoclasts.
- RNKL Receptor activator of NF- ⁇ B
- the receptor activator of NF- ⁇ B causes the sequential recruitment of adapter molecules responsible for activation of signaling processes. These pathways lead to activation of protein kinases, which in turn activate transcription factors leading to changes in gene expression that alter the function of the cell.
- osteoclast formation may be attributed to the relative ratio of the receptor activator of NF- ⁇ B ligand to osteoprotegerin in the microenvironment of bone marrow, and alterations in this balance may be a major cause of bone loss in many metabolic bone disorders.
- RANK/RANKL/osteoprotegerin have a major role in bone diseases and cancer-induced bone destruction that are due to increased osteoclastic activity.
- the cytoplasmic domain of receptor activator of NF- ⁇ B interacts with TRAF family members, specifically TRAF1, 2, 3, 5, and 6. Stimulation of the receptor activator of NF- ⁇ B activates members of the MAPK family (i.e., JNK, p38, ERK) and IKKs, which lead to activation of transcription factors AP1 and NF- ⁇ B.
- TRAF2, TRAF5, and TRAF6 with receptor activator of NF- ⁇ B have been reported and it was demonstrated that receptor activator of NF- ⁇ B could activate both the NF- ⁇ B and JNK pathways. Subsequently, a novel TRAF6 binding motif was identified in receptor activator of NF- ⁇ B that is distinct from the TRAF2 and TRAF5 binding domains.
- TRAF6 binding domain in the receptor activator of NF- ⁇ B was sufficient for activation of NF- ⁇ B, suggesting that TRAF2 and TRAF5 are not necessary for NF- ⁇ B activation.
- TRAF6-deficient mice develop osteopetrosis due to a defect in osteoclastogenesis, which is not found in either the TRAF2- or TRAF5-deficient mice.
- TRAF6 appears to be the critical adapter protein for the receptor activator of NF- ⁇ B signaling
- the present invention develops a novel TRAF6 decoy peptide (T6DP) with and without a peptide leader sequence that allows for transversing cellular membrane.
- T6DP TRAF6 decoy peptide
- Evidence disclosed herein indicate that the TRAF6-decoy peptide inhibits RANKL signaling transduction and RANKL-mediated osteoclast differentiation, but only when the leader sequence is attached.
- the present invention is drawn to polypeptides that inhibit signaling mediated by TNF receptor-associated factor 6 (TRAF6). These polypeptides comprise a TRAF6 binding domain and a leader signal sequence.
- TRAF6 inhibitory polypeptides A number of approaches may be utilized by a person having ordinary skill in this art to search for TRAF6 inhibitory polypeptides; two approaches are, for example, screening peptide libraries or synthesizing overlapping peptides from the cytoplasmic domains of RANK or TRAF6.
- the polypeptide comprises of sequence selected from the group consisting of SEQ ID No. 19 and 20.
- TRAF6 also mediates signaling induced by a number of molecules such as IL-1, LPS, IL-18, and CD40L
- the polypeptides claimed herein may inhibit RANKL mediated signaling as well as signaling induced by these other molecules.
- the polypeptides disclosed herein may contain a TRAF6 binding domain derived from CD40, Receptor Activator of NF- ⁇ B, IL-1 receptor-associated kinase 1 (IRAK1), IL-1 receptor-associated kinase 2 (IRAK2), IRAK-M or RIP2.
- the TRAF6 binding domain comprises of sequence selected from the group consisting of SEQ ID No. 1-18.
- leader signal sequence attached to the TRAF6 binding domain in the polypeptides disclosed herein may be derived from a number of different proteins.
- Representative leader signal peptides include Kaposi fibroblast growth factor signal sequence, HIV-1 Tat (48-60), D-amino acid-substituted HIV-1 Tat (48-60), arginine-substituted HIV-1 Tat (48-60), Drosophila Antennapaedia (43-58), viral RNA binding peptide that comprises 7 or more arginines, DNA binding peptide that comprises 7 or more arginines and polyarginine polypeptide that has 6 to 8 arginines.
- These arginine-rich signal sequences that can be used for delivery of exogenous proteins into cells are well known in the art (39).
- Futaki et al. (39) has reported various arginine-rich peptides that have translocation activities very similar to that of HIV-1 Tat (48-60). These arginine-rich peptides include HIV-1 Rev (34-50), HTLV-II Rev (4-16), brome mosaic virus Gag (7-25), flock house virus coat protein (35-49), human c-Fos (139-164), human c-Jun (252-279) and yeast transcription factor GCN4 (231-252).
- the present invention is also drawn to a method of inhibiting Receptor Activator of NF- ⁇ B Ligand (RANKL)-induced osteoclast differentiation using the polypeptides disclosed herein, wherein inhibition of interaction between the receptor activator of NF- ⁇ B and TRAF6 by these polypeptides result in inhibition of RANKL-induced osteoclast differentiation.
- This method can be used to inhibit osteoclast differentiation induced by breast cancer cells.
- the polypeptide can be applied to the cells by a number of methods well known in the art such as liposomes, viruses or other gene delivery vectors.
- the ProVectinTM protein delivery reagent is a unique lipid-based formulation that allows delivery of the polypeptides disclosed herein or other bioactive molecules into a broad range of cell types.
- the present invention there is also provided a method of inhibiting osteoclast differentiation in a n individual by the polypeptide inhibitors disclosed herein.
- the individual would have a disease comprising a metabolic bone disorder, leukemia, arthritis, multiple myeloma, or metastatic cancer of the bone.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the polypeptide inhibitors disclosed herein.
- pharmaceutically acceptable refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a subject.
- the preparation of an aqueous composition that contains a protein as an active ingredient is well understood in the art.
- the active composition(s) of the present invention is administered to the patient or an animal in therapeutically effective amounts, i.e., amounts that inhibit RANKL-mediated osteoclast differentiation. See Remington's Pharmaceutical Science, 17th Ed. (1990) Mark Publishing Co., Easton, Penn.; and Goodman and Gilman's: The Pharmacological Basis of Therapeutics 8th Ed (1990) Pergamon Press.
- the present invention is further drawn to non-peptide analogs that mimic the functions of the polypeptide disclosed herein, wherein these non-peptide analogs inhibit signaling mediated by TRAF6.
- Low molecular weight, non-peptide molecules that mimic the inhibitory polypeptides disclosed herein can serve as robust tools to help establish the role of TRAF6-mediated signaling in models of physiological and pathophysiological processes as well as serving as therapeutic agents in their own right.
- a number of reports have disclosed the rationale and strategy for the design of low molecular weight, non-peptide molecules that are amenable to high resolution analysis and rapid modification (40-42).
- the present invention is also drawn to a method of inhibiting Receptor Activator of NF- ⁇ B Ligand (RANKL)-induced osteoclast differentiation using these non-peptide analogs, wherein inhibition of interaction between the receptor activator of NF- ⁇ B and TRAF6 by said non-peptide analogs result in inhibition of RANKL-induced osteoclast differentiation.
- This method can be used to inhibit osteoclast differentiation induced by breast cancer cells.
- the human embryonic kidney 293 cell line and the mouse macrophage cell line RAW264.7 were obtained from the American Type Culture Collection (Rockville, Md.). The 293 cells were cultured in MEM supplemented with 10% fetal bovine serum and antibiotics. RAW264.7 cells were cultured in DMEM-F12 supplemented with 10% fetal bovine serum and antibiotics. Monoclonal antibodies to phospho-ERK, p38, and JNK were purchased from New England Biolabs. Goat anti-rabbit IgG-conjugated horseradish peroxidase was purchased from BioRad Laboratories (Hercules, Calif.). Anti-JNK1 and anti-I ⁇ B were purchased from Santa Cruz Biotechnology (Santa Cruz, Calif.).
- Goat anti-mouse IgG-conjugated horseradish peroxidase was purchased from Transduction Laboratories (Lexington, Ky.). Protein A/G Sepharose beads was purchased from Pierce (Rockford, Ill.), and anti-FLAG was purchased from Sigma (St. Louis, Mo.). Staining for tartrate resistance acid phosphatase (TRAP) positive osteoclasts was performed essentially as described (30) or by using an acid phosphatase kit from Sigma.
- TRIP tartrate resistance acid phosphatase
- Expression plasmids encoding mouse FLAG-tagged TRAF5 and TRAF6 (31) were provided by H. Nakano (Juntendo University, Tokyo, Japan) and FLAG-tagged TRAF2 was provided by J. Ni (Human Genome Sciences, Inc.). Expression vectors and purification of GST-fusion proteins for GST, GST-receptor activator of NF- ⁇ B cytoplasmic domain, and GST-Jun (1-79) have been previously described (7, 8).
- the expression vector of full-length murine RANKL also known as TNF-related activation-induced cytokine (TRANCE) (pcDNA3.1-TRANCE) was provided by Y. Choi (Rockefeller University, New York, N.Y.).
- BM Primary bone marrow monocytes
- RAW264.7 cells were cultured in 48-well dishes at a density of 1 ⁇ 10 5 cells/well or 2 ⁇ 10 3 cells/well, and then treated with the indicated factors at the beginning of the culture and during a medium change on day 3. Osteoclast formation was assessed by counting the total number of multi-nucleated (>3 nuclei), TRAP-positive cells present per well between day 7 and 10 (BM) or on day 5 (RAW264.7) (30).
- the beads were collected by centrifugation, washed three times in binding buffer, and then washed once in low-salt buffer (20 mM TRIS, pH 8, 50 mM NaCl, and 1 mM DTT). Bound proteins were eluted with addition of SDS-sample buffer and boiled. The eluted proteins were subjected to 7.5% SDS-PAGE and western blot analysis was performed with anti-FLAG antibodies.
- Lysates were prepared from RAW cells stimulated with RANKL as indicated in the legends to the figures. Approximately 30 ⁇ g was then used for immunoprecipitation with indicated antibodies and protein A/G Sepharose beads for 1 h. Beads were collected by centrifugation, washed three times in lysis buffer, and then washed two times in low-salt buffer. JNK activity was analyzed using exogenous GST-Jun (1-79) as a substrate as previously described (8). Kinase activity was quantitated using a PhosphoImager and Imagequant Software (Molecular Dynamics, Sunnyvale, Calif.).
- Nuclear extracts were prepared from transfected cells essentially as described (34). Equivalent amounts of nuclear protein were used in an EMSA reaction with 32 P-labeled NF- ⁇ B oligonucleotide from HIV-LTR as described (34). NF- ⁇ B activation was quantitated using a PhosphoImager and Imagequant Software.
- a novel TRAF6 binding domain in RANK which binds to only TRAF6 but not TRAF2 or TRAF5, has been identified previously (8).
- this region of the receptor activator of NF- ⁇ B was sufficient for activation of NF- ⁇ B (8).
- Structure-based sequence alignment of TRAF6-binding sites in human and mouse CD40 and RANK led to the definition of a TRAF6-binding motif PxExx(Ar/Ac) (Ar for aromatic and Ac for acidic residues) (FIG. 1A).
- Careful examination of the RANK sequence indicates that there are three potential TRAF6-binding sites (FIG. 1A).
- TRAF6 is the only TRAF family member that participates in the signal transduction of both the TNF receptor superfamily and the interleukin-1 receptor (IL-1R)/Toll-like receptor (TLR) superfamily.
- the best-characterized TRAF6 signaling pathway for the IL-1R/TLR superfamily involves IRAK, an adapter kinase upstream of TRAF6. Upon receptor stimulation, IRAK becomes oligomerized and interacts with TRAF6 (43). It was found that full-length IRAK contains three potential TRAF6-binding sites (FIG. 1A).
- Two IRAK homologues, IRAK-2 and IRAK-M also contain two and a single potential TRAF6-binding site, respectively (FIG. 1A).
- TRAF6-binding site (FIG. 1A). The presence of TRAF6-binding sites in these various molecules suggests that TRAF6 may play a role in mediating multiple signaling cascades.
- Delivery of peptides or proteins across cellular membranes can be achieved by covalent attachment of the peptide to molecules that can freely pass through the membrane (35).
- the hydrophobic domain of Kaposi fibroblast growth factor signal sequence was attached to the nuclear localization signal from the p50 subunit of NF- ⁇ B to allow for translocation across the membrane (36).
- this hydrophobic sequence was attached to peptides derived from murine RANK, namely L-T6DP-1 which contains the known TRAF6 binding domain and L-T6DP-2 which contains a similar motif (FIG. 1B).
- both of these peptides were synthesized without the leader sequence, resulting in peptides that were not be able to transverse cellular membrane (FIG. 1B).
- TRAF6-decoy Peptides Inhibit RANKL-mediated Osteoclast Differentiation in RAW264.7 Cells
- the mouse macrophage cell line RAW264.7 express the receptor activator of NF- ⁇ B on their cell surface and when stimulated with the receptor activator of NF- ⁇ B ligand differentiate into multi-nucleated, tartrate resistant acid phosphatase (TRAP) positive osteoclasts after 4-5 days (FIG. 2A).
- TREP tartrate resistant acid phosphatase
- L-T6DP-1 could inhibit RANKL-mediated osteoclast differentiation
- RAW264.7 cells were co-cultured with increasing concentrations of either L-T6DP-1. or T6DP-1 and 30 ng/ml RANKL for 4 days.
- TRAF6decoy peptide without leader sequence failed to block RANKL-mediated osteoclast differentiation; however, treatment with L-T6DP-1 caused a dose-dependent inhibition of osteoclast differentiation. Although the cells were TRAP positive after treatment with 100 ⁇ M L-T6DP-1, multi-nucleated osteoclast were not observed (FIG. 2B). Furthermore, treatment of RAW264.7 cells with RANKL in the presence of either L-T6DP-1 or L-T6DP-2 caused a dose-dependent decrease of TRAP positive osteoclasts (FIG. 2C), although L-T6DP-1 was much more efficient than L-T6DP-2.
- TRAF6decoy Peptides Inhibit RANKL-mediated Osteoclast Differentiation in Bone Marrow-derived Mouse Monocytes
- TRAF6decoy peptides without the leader sequences failed to inhibit osteoclast differentiation (FIG. 3), indicating that the peptides were not toxic to the cells.
- the cells were TRAP positive after treatment with 30 ⁇ M L-T6DP-1, multi-nucleated osteoclast were not observed and at 100 ⁇ M L-T6DP-1, no osteoclasts were observed (FIG. 3B).
- these results indicate that interaction of TRAF6 with RANK is essential for RANKL-mediated osteoclast differentiation.
- TRAF6Decoy Peptide Inhibits RANKL-mediated NF-kB Activation i n RAW264.7 Cells
- a mutant form of the receptor activator of NF- ⁇ B which contains only the TRAF6 binding domain is sufficient to activate NF- ⁇ B (8), and a dominant negative TRAF6 inhibits RANK-mediated NF- ⁇ B activation in 293 cells (9).
- TRAF6 binding peptides bind to RANKL-induced NF- ⁇ B activation
- NF- ⁇ B activation was examined in RAW264.7 cells that activated NF- ⁇ B when stimulated with RANKL (37).
- RANKL-stimulated RAW264.7 cells activated NF- ⁇ B as indicated by a gel mobility shift assay (FIG. 4A).
- NF- ⁇ B activation was suppressed in a dose-dependent manner only by pre-treatment with L-T6DP-1 (FIG. 4A).
- the levels of I ⁇ B ⁇ coincided with the activation and repression of NF- ⁇ B as indicated in FIG. 4B.
- TRAF6Decoy Peptide Specifically Inhibits TRAF6 Binding to the RANK Cytoplasmic Domain
- the cytoplasmic domain of RANK interacts with many TRAF molecules, including TRAF1, 2, 3, 5, and 6 (7-9, 11, 12). While TRAF1, 2, 3, and 5 interact with the c-terminal tail of receptor activator of NF- ⁇ B, TRAF6 interacts with a membrane proximal region of the cytoplasmic domain of the receptor activator of NF- ⁇ B. To confirm that the TRAF6-binding peptides disclosed herein were specifically inhibiting TRAF6 interaction with RANK, a competitive GST-pull down assay was performed.
- TRAF6Decoy Peptide Specifically Inhibits JNK, ERK, and p38 Kinase Activation by RANKL in RAW264.7 Cells
- L-T6DP-1 is able to suppress the receptor activator of NF- ⁇ B ligand-mediated osteoclast differentiation and the receptor activator of NF- ⁇ B ligand-initiated early signaling including NF- ⁇ B, JNK, ERK, and p38 kinase activation.
- Breast cancer is the most common female malignancy in the U.S. and is the second leading cause of cancer death in women. Women with breast cancer are at risk for bone metastases. Five to ten percent of patients with breast cancer initially present with metastatic disease to the bone. Patients with osteolytic bone disease from metastatic breast cancer are at increased risk for pathologic fractures, bone pain, cord compression and hypercalcemia. Current standard of care for treating bone metastases is bisphosphonate therapy which delays skeletal events but does not completely prevent them. In addition, not all patients respond to this treatment. While a more effective treatment is desired, a further biological and molecular dissection of this disease is required. In fact, recently it was demonstrated that osteoprotegerin (OPG) inhibits osteolysis and decreases tumor burden in nude mouse models injected with breast cancer cells.
- OPG osteoprotegerin
- a co-culture assay system was developed for RAW cells and the osteoblast-like cell (osteosarcoma MG-63) which has been shown to express the receptor activator of NF- ⁇ B ligand and cause osteoclast differentiation.
- the number of MG-63 cells was critical for inducing RAW cells to differentiate into osteoclasts.
- FIG. 6A results using RAW cells co-cultured with MG-63 (data not shown) or with breast cancer cell lines (i.e., T47D and MDA-MB-468) indicated that these breast cancer cells could in fact cause RAW cells to form TRAP + , multi-nucleated osteoclasts after 4 days (FIG. 6A) similar to RAW cells stimulated with the receptor activator of NF- ⁇ B ligand.
- the breast cancer cell lines were grown in tissue culture inserts where they were separated from RAW cells by a membrane, osteoclast still formed, suggesting that direct cell-to
- ELISA-based method similar to one described previously ( J. Biol. Chem., 276:12235-12240, 2001) can be used to discover small molecules that inhibit RANK-TRAF6 interaction. Briefly, peptides comprising the T6DP are biotinylated, dissolved in TRIS-buffered saline (50 mM TRIS pH 7.5, 150 mM NaCl), and added to wells in NeutrAvidin-coated 96-well microtiter plates. The plates are shaken overnight at 4° C. and then rinsed with TBS followed by TBS-BT (TBS containing 0.1%bovine serum albumin (BSA) and 0.1% Tween 20).
- TBS TBS-BT
- a solution containing a test small molecule from a library is then added to the well.
- a solution containing 6 ⁇ -histidine-tagged TRAF6 (309-522) is then added to each well.
- the plates are 4 incubated for 1 h at room temperature and then washed 3 times with TBS-BT.
- An antibody directed against the C-terminus of TRAF6 is then added to the wells and the plates are incubated for 1 hour a t room temperature, followed by 3 washes with TBS-BT.
- a secondary antibody consisting of goat anti-mouse alkaline phosphatase is then added to each well and the plates are incubated for 1 hour at room temperature, followed by 3 washes with TBS-BT.
- the plates are then assayed for alkaline phosphatase activity using a fluorescent plate reader as previously described (Darnay et al., J. Biol. Chem. 274:7724-7731, 1999).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
- This non-provisional patent application claims benefit of provisional patent application U.S. Ser. No. 60/290,429, filed May 11, 2001, now abandoned.
- 1. Field of the Invention
- The present invention relates generally to the fields of cytokine biology and bone diseases. More specifically, the present invention provides inhibitors of receptor activator of NF-κB (RANK) for therapy of disorders such as diseases associated with bone resorption.
- 2. Description of the Related Art
- Members of the TNF and TNF receptor superfamilies play critical roles in the initiation and regulation of the immune response (1-3). Although members of these families share many overlapping biological functions, it appears from gene knockout studies that they have unique features. One such receptor/ligand pair, receptor activator of NF-κB (RANK) and its ligand (RANKL/TRANCE/ODF/OPGL), is critically involved in regulation of bone remodeling and osteoclastogenesis (4). From knockout gene studies in mice, RANKL also functions in lymph node organogenesis and lymphocyte development (5). Furthermore, receptor activator of NF-κB and RANKL are implicated in the interactions between T cells and dendritic cells during the immune response (6).
- As indicated by its name, receptor activator of NF-κB stimulates activation of nuclear factor-κB (NF-κB) (7-12), a transcription factor that regulates the expression of a large number of genes that play essential roles in immune and inflammatory responses (13). Evidence over the past several years has indicated that some of the TNF receptor family members interact with a family of adapter proteins known as TRAFs, (TNF receptor-associated factors), which participate in activation of the transcription factor NF-κB and c-Jun N-terminal kinase (JNK) (14).
- The TNF receptor-associated factor family consists of six distinct proteins, each of which possesses a C-terminal homologous domain that is critical for self-association and is required for interaction with the receptors. All of the TNF receptor-associated factors, except for TRAF1 and TRAF4, also contain ring and zinc finger motifs in their N-termini, which appear to be utilized for interacting with other signaling molecules. Similar to the trimeric structure of the ligands and receptors of the TNF family, the C-terminus of the TRAF2 adapts a trimeric structure, as reported for TRAF2 in its interaction with peptides derived from
TNF receptor 1 and CD40 (15, 16). This trimeric structure of the TNF receptor-associated factor molecules likely enables them to associate with downstream adapter proteins. - It has been demonstrated that TRAF2, TRAF5, and TRAF6 interact with receptor activator of NF-κB (RANK) and that receptor activator of NF-κB could activate both the NF-κB and JNK pathways (7). Subsequently, a more detailed analysis of the interaction of these TNF receptor-associated factors with receptor activator of NF-κB was reported (8). A novel TRAF6-binding motif has been identified in RANK that is distinct from the TRAF2- and TRAF5-binding domains. A homologous TRAF6-binding motif in CD40 was described using a combinatorial peptide library approach (17). The TRAF6 binding domain in RANK was sufficient for activation of NF-κB , suggesting that TRAF2 and TRAF5 are not necessary for NF-κB activation. However, it appears that the TRAF2-binding motif is sufficient for JNK activation, although the TRAF6-binding domain could also activate JNK, albeit to a lesser extent. Additionally, NIK (NF-κB inducing kinase) was also found to be required for the activation of NF-κB by receptor activator of NF-κB. In addition to TRAF2, TRAF5, and TRAF6, it has been demonstrated that TRAF1 and TRAF3 also associate with the carboxy terminus of receptor activator of NF-κB (9-12).
- The role played by each TRAF molecule in RANK signal transduction remains elusive. Dominant negative mutants of TRAF2, TRAF5, and TRAF6 have been used to evaluate their role in NF-κB activation by RANK. It appears that all of the dominant negative TRAFs differentially inhibit the activation of NF-κB induced b y overexpression of RANK in 293 cells (9, 12). However, inclusion of all dominant negative mutants of TRAF2, TRAF5, and TRAF6 did not completely eliminate the activation of NF-κB induced by RANK in 293 cells (12). Stimulation of RANK also caused the recruitment of TRAF6, which in turn recruits and activates c-Src, which appears to be responsible for activation of phosphoinositol-3-kinase and protein kinase B/AKT, a molecule potentially involved in cell survival (18).
- Knockout mouse models of RANKL, RANK, and osteoprotegerin have demonstrated an essential role of these molecules in osteoclastogenesis. The biological importance of these molecules is underscored by the induction of severe osteoporosis by targeted disruption of osteoprotegerin and by the induction of osteopetrosis by targeted disruption of RANKL or by overexpression of osteoprotegerin (5, 19, 20). Thus, osteoclast formation may b e attributed to the relative ratio of RANKL to osteoprotegerin in the microenvironment of bone marrow, and alterations in this balance may be a major cause of bone loss in many metabolic bone disorders.
- Similar to RANKL-/-mice, targeted disruption of receptor activator of NF-κB also lead to an osteopetrotic phenotype (21, 22). Both RANK-/- and RANKL-/-mice exhibited absence of osteoclasts, indicating the essential requirement of these molecules for osteoclastogenesis. Additionally, mice lacking TRAF6 (23-25), c-Src (26), c-Fos (27), or the NF-κB subunits p50/p52 (28, 29) also display an osteopetrotic phenotype. Although these mutant mice have osteoclasts, these cells apparently have defects in bone resorption. Thus, RANKL and receptor activator of NF-κB as well as their cytoplasmic signaling molecules are required for osteoclastogenesis.
- Of the TRAF molecules that bind to receptor activator of NF-κB, only TRAF6 appears to be essential for osteoclast differentiation as indicated in mice lacking TRAF6. Thus, t h e interaction of receptor activator of NF-κB with TRAF6 may be a unique target for therapeutic intervention, and the ability to disrupt this interaction by a competitive, cell permeable peptide remains to be investigated.
- Thus, the prior art is deficient in methods of disrupting the interaction between receptor activator of NF-κB and TRAF6 in order to inhibit RANKL signaling and osteoclast differentiation induced by RANKL. Such inhibitors would be useful as therapeutics in bone disorders and cancer associated with increased bone resorption. The present invention fulfills this long-standing need and desire in the art.
- TRAF6 (TNF receptor-associated factor 6) is a critical adapter protein for Receptor Activator of NF-κB (RANK) signaling. The present invention discloses a novel TRAF6 decoy peptide (T6DP) with and without a peptide leader sequence that allows for transversing the cellular membrane. Evidence disclosed herein indicate that the TRAF6 decoy peptide inhibits early events associated with RANKL signaling and RANKL-mediated osteoclast differentiation only when the leader sequence is attached. This data indicates that targeted disruption of interaction between Receptor Activator of NF-κB and TRAF6 may prove useful as a therapeutic for metabolic bone disorders, leukemia, arthritis, and metastatic cancer of the bone.
- The present invention provides polypeptides that inhibit signaling mediated by TNF receptor-associated factor 6 (TRAF6), wherein the polypeptides comprise of a TRAF6 binding domain and a leader signal sequence. The present invention is further drawn to methods of inhibiting Receptor Activator of NF-κB Ligand (RANKL)-induced osteoclast differentiation using the polypeptides disclosed herein.
- In another aspect of the present invention, there is provided a non-peptide analog that mimics the function of the polypeptide disclosed herein, wherein said non-peptide analog inhibits signaling mediated by TRAF6. The present invention is further drawn to methods of inhibiting Receptor Activator of NF-κB Ligand (RANKL)-induced osteoclast differentiation using a non-peptide analog that mimics the function of the polypeptide disclosed herein.
- Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention. These embodiments are given for the purpose of disclosure.
- So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.
- FIG. 1 shows the novel TRAF6 binding domain in RANK. FIG. 1A shows the consensus sequence of the TRAF6 binding domain. The region within the amino acid sequence of CD40 (residues 230-245) that specifically interacts with TRAF6 (38) was used as the template for alignment of RANK, IRAK1, and IRAK2. Identical residues are in bold. A consensus motif is shown on the bottom.
- FIG. 1B shows the peptides used in the present study. The hydrophobic domain of Kaposi fibroblast growth factor signal sequence (underlined) (36) was attached to the two potential TRAF6 binding domains from murine receptor activator of NF-κB. Additionally, two peptides lacking the leader sequence were synthesized.
- FIG. 2 shows L-T6Bp-1 inhibits RANKL-mediated osteoclast differentiation in RAW264.7 cells. FIG. 2A shows RANKL-induces TRAP positive osteoclasts. RAW264.7 cells were plated in 12-well plates and stimulated with RANKL (30 ng/ml) for 4 days. Cells were stained for TRAP essentially as described below. Photographs were taken using a 10× objective lens.
- FIG. 2B shows L-T6DP-1 inhibits osteoclast differentiation. RAW cells were plated as described in FIG. 2A and treated with RANKL in the presence of 1, 30, or 100 μM of peptides as indicated. On day 4 cells were stained and evaluated as in FIG. 2A.
- FIG. 2C shows L-T6DP-1 inhibits the total number of TRAP positive osteoclasts induced by RANKL. RAW264.7 cells were plated in 48-well plates in triplicate and treated with RANKL in the presence of increasing amounts of the indicated peptides. After 4-5 days, the cells were stained for TRAP and the total numbers of osteoclasts were counted as described below.
- FIG. 3 shows leader TRAF6-binding peptide inhibits normal mouse derived osteoclast differentiation by RANKL and M-CSF. FIG. 3A shows mouse-derived monocytes were plated in 48-well plates in triplicate and costimulated with murine M-CSF (10 ng/ml) and RANKL(30 ng/ml) in the absence (0) or presence of the indicated peptides. After 6-7 days, the cells were fixed and stained for TRAP. The numbers of multi-nucleated, TRAP positive osteoclasts were counted.
- FIG. 3B shows LT6DP-1 inhibits osteoclast differentiation of mouse-derived monocytes. Mouse-derived monocytes were plated in 48-well plates and costimulated as in FIG. 3A with murine M-CSF (10 ng/ml) and RANKL (30 ng/ml) in the absence (left panel) or presence of the indicated peptides. After 6-7 days, the cells were fixed and stained for TRAP. A representative field from each well was taken at a magnification of 10×.
- FIG. 4 shows that L-T6DP-1 specifically inhibits RANKL-induced NF-κB activation and TRAF6 binding. FIG. 4A shows inhibition of RANKL-mediated NF-κB activation by L-T6Bp-1. RAW264.7 cells were plated in 6-well plates and treated with the indicated peptides for 5 h, then treated with RANKL (10 nM) for 15 min. Nuclear and cytoplasmic extracts were prepared and a gel mobility shift assays was performed with 8 μg of nuclear extracts as described below.
- FIG. 4B shows inhibition of IκB degradation by L-T6DP-1. Cytoplasmic extracts (30 μg) from FIG. 4A were immunoblotted with anti-IκB as described below.
- FIG. 4C shows L-T6DP-1 inhibits TRAF6 from binding to the receptor activator of NF-κB cytoplasmic domain. Cellular extracts from human 293 cells transfected with either FLAG-TRAF2, -TRAF5, or -TRAF6 were mixed with GST or GST-RANKcd in the absence or presence of 100 μM of the indicated peptides. A GST-pull down assay was performed as described below. The bound TRAFs were visualized by immunoblotting with anti-FLAG antibodies.
- FIG. 5 shows L-T6DP-1 specifically inhibits RANKL-induced JNK, ERK, and p38 kinase activation. FIG. 5A shows inhibition of RANKL-mediated JNK activation by L-T6DP-1. RAW264.7 cells were plated in 6-well plates and treated with the indicated peptides for 6 h, then treated with RANKL (10 nM) for 1 5 min. Whole cell extracts were prepared and 30 μg of cell lysate was immunoprecipitated with anti-JNK1. In vitro kinase assays were performed using GST-Jun (1-79) as the substrate as described below.
- FIG. 5B and FIG. 5C show inhibition of RANKL-mediated ERK and p38 activation by L-T6DP-1. Whole cell extracts (30 μg) from FIG. 5A were separated by 10% SDS-PAGE and electroblotted onto a nitrocellulose membrane. The membranes were first immunoblotted with the indicated phospho-specific antibody and then stripped and re-probed with the indicated antibodies as described below.
- FIG. 6 shows L-T6DP-1 inhibits osteoclast differentiation induced by breast cancer cells. FIG. 6A: Breast cancer cells (500/well) were plated in 24-well plates in the absence or presence of RAW cells (10000/well) and in the absence or presence of L-T6DP-1 or T6DP-1 (100 μM). After 5 days, the cells were fixed, stained for TRAP, and photographed with a 10× objective lens.
- FIG. 6B shows RAW cells were cultured alone or in the presence of the indicated cells on synthetic bone slides (BD BiCoat Osteologic MultiTest Slides). After 6 days, the cells were removed b y washing the slide in bleach for 5 minutes and then washing thoroughly with distilled water. The slide was air dried and then photographs were taken with a light microscope (10× objective lens). The ghosts of osteoclasts (arrow) can be seen where functional osteoclasts destroyed the synthetic bone matrix.
- FIG. 6C shows normal breast epithelial cells (MCF10A, 1000/well) grown in the presence of RAW and stained for TRAP as indicted in FIG. 6A. The right panel includes the addition of RANKL (100 ng/ml) to the co-culture.
- Receptor activator of NF-κB (RANK), a recently described member of the TNF receptor superfamily, is expressed primarily b y dendritic cells, osteoclast progenitors, activated B and T cells and osteoclasts. By binding to its ligand (RANKL), the receptor activator of NF-κB causes the sequential recruitment of adapter molecules responsible for activation of signaling processes. These pathways lead to activation of protein kinases, which in turn activate transcription factors leading to changes in gene expression that alter the function of the cell.
- Knockout mouse models of RANKL, RANK, and osteoprotegerin (OPG), a secreted soluble receptor that binds RANKL, have demonstrated an essential role of these molecules in osteoclastogenesis (i.e., bone remodeling). The biological importance of these molecules is underscored by the induction of severe osteoporosis by targeted disruption of osteoprotegerin and by the induction of osteoperosis by targeted disruption of RANKL, the receptor activator of NF-κB, or by transgenic expression of osteoprotegerin. These results indicate that osteoclast formation may be attributed to the relative ratio of the receptor activator of NF-κB ligand to osteoprotegerin in the microenvironment of bone marrow, and alterations in this balance may be a major cause of bone loss in many metabolic bone disorders. Hence, RANK/RANKL/osteoprotegerin have a major role in bone diseases and cancer-induced bone destruction that are due to increased osteoclastic activity.
- In addition to osteoporosis, recent reports suggest a potential role of these molecules in other diseases including rheumatoid arthritis, giant cell tumor of bone, Paget's disease, and familial expansile osteolysis (due to a mutation in
exon 1 of the receptor activator of NF-κB ). A T cell lymphoproliferative disorder has also been identified in which dysregulation of the receptor activator of NF-κB and RANKL contributes to the survival of malignant T cell clone. - It has been recognized that breast and prostate cancers have the ability to invade and grow as metastases in bone causing osteolytic lesions. In metastatic tumor mouse models in which the tumor causes increased osteoclastogenesis and bone destruction, systemic administration of osteoprotegerin reduces tumor-mediated bone destruction and pain associated with bone cancer. Thus, development of drugs that target inhibition of the receptor activator of NF-κB signaling are potential therapeutics for metabolic bone disorders and cancer.
- The cytoplasmic domain of receptor activator of NF-κB interacts with TRAF family members, specifically TRAF1, 2, 3, 5, and 6. Stimulation of the receptor activator of NF-κB activates members of the MAPK family (i.e., JNK, p38, ERK) and IKKs, which lead to activation of transcription factors AP1 and NF-κB. The interactions of TRAF2, TRAF5, and TRAF6 with receptor activator of NF-κB have been reported and it was demonstrated that receptor activator of NF-κB could activate both the NF-κB and JNK pathways. Subsequently, a novel TRAF6 binding motif was identified in receptor activator of NF-κB that is distinct from the TRAF2 and TRAF5 binding domains.
- The TRAF6 binding domain in the receptor activator of NF-κB was sufficient for activation of NF-κB, suggesting that TRAF2 and TRAF5 are not necessary for NF-κB activation. In support of these findings, TRAF6-deficient mice develop osteopetrosis due to a defect in osteoclastogenesis, which is not found in either the TRAF2- or TRAF5-deficient mice.
- Since TRAF6 appears to be the critical adapter protein for the receptor activator of NF-κB signaling, the present invention develops a novel TRAF6 decoy peptide (T6DP) with and without a peptide leader sequence that allows for transversing cellular membrane. Evidence disclosed herein indicate that the TRAF6-decoy peptide inhibits RANKL signaling transduction and RANKL-mediated osteoclast differentiation, but only when the leader sequence is attached. These data indicate that targeted disruption of the interaction between receptor activator of NF-κB and TRAF6 would be useful as a therapeutic for metabolic bone disorders, leukemia, multiple myeloma, arthritis, and metastatic cancer of the bone.
- The present invention is drawn to polypeptides that inhibit signaling mediated by TNF receptor-associated factor 6 (TRAF6). These polypeptides comprise a TRAF6 binding domain and a leader signal sequence. A number of approaches may be utilized by a person having ordinary skill in this art to search for TRAF6 inhibitory polypeptides; two approaches are, for example, screening peptide libraries or synthesizing overlapping peptides from the cytoplasmic domains of RANK or TRAF6. In one embodiment of the present invention, the polypeptide comprises of sequence selected from the group consisting of SEQ ID No. 19 and 20. Since TRAF6 also mediates signaling induced by a number of molecules such as IL-1, LPS, IL-18, and CD40L, the polypeptides claimed herein may inhibit RANKL mediated signaling as well as signaling induced by these other molecules.
- The polypeptides disclosed herein may contain a TRAF6 binding domain derived from CD40, Receptor Activator of NF-κB, IL-1 receptor-associated kinase 1 (IRAK1), IL-1 receptor-associated kinase 2 (IRAK2), IRAK-M or RIP2. Preferably, the TRAF6 binding domain comprises of sequence selected from the group consisting of SEQ ID No. 1-18.
- The leader signal sequence attached to the TRAF6 binding domain in the polypeptides disclosed herein may be derived from a number of different proteins. Representative leader signal peptides include Kaposi fibroblast growth factor signal sequence, HIV-1 Tat (48-60), D-amino acid-substituted HIV-1 Tat (48-60), arginine-substituted HIV-1 Tat (48-60), Drosophila Antennapaedia (43-58), viral RNA binding peptide that comprises 7 or more arginines, DNA binding peptide that comprises 7 or more arginines and polyarginine polypeptide that has 6 to 8 arginines. These arginine-rich signal sequences that can be used for delivery of exogenous proteins into cells are well known in the art (39). For example, Futaki et al. (39) has reported various arginine-rich peptides that have translocation activities very similar to that of HIV-1 Tat (48-60). These arginine-rich peptides include HIV-1 Rev (34-50), HTLV-II Rev (4-16), brome mosaic virus Gag (7-25), flock house virus coat protein (35-49), human c-Fos (139-164), human c-Jun (252-279) and yeast transcription factor GCN4 (231-252).
- The present invention is also drawn to a method of inhibiting Receptor Activator of NF-κB Ligand (RANKL)-induced osteoclast differentiation using the polypeptides disclosed herein, wherein inhibition of interaction between the receptor activator of NF-κB and TRAF6 by these polypeptides result in inhibition of RANKL-induced osteoclast differentiation. This method can be used to inhibit osteoclast differentiation induced by breast cancer cells. The polypeptide can be applied to the cells by a number of methods well known in the art such as liposomes, viruses or other gene delivery vectors. For example, the ProVectin™ protein delivery reagent is a unique lipid-based formulation that allows delivery of the polypeptides disclosed herein or other bioactive molecules into a broad range of cell types.
- In another aspect of the present invention, there is also provided a method of inhibiting osteoclast differentiation in a n individual by the polypeptide inhibitors disclosed herein. In general, the individual would have a disease comprising a metabolic bone disorder, leukemia, arthritis, multiple myeloma, or metastatic cancer of the bone.
- The present invention also provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the polypeptide inhibitors disclosed herein. The phrase “pharmaceutically acceptable” refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a subject. The preparation of an aqueous composition that contains a protein as an active ingredient is well understood in the art.
- A person having ordinary skill in this art would readily b e able to determine, without undue experimentation, the appropriate dosages and routes of administration of the active component of the present invention. When used in vivo for therapy, the active composition(s) of the present invention is administered to the patient or an animal in therapeutically effective amounts, i.e., amounts that inhibit RANKL-mediated osteoclast differentiation. See Remington's Pharmaceutical Science, 17th Ed. (1990) Mark Publishing Co., Easton, Penn.; andGoodman and Gilman's: The Pharmacological Basis of Therapeutics 8th Ed (1990) Pergamon Press.
- The present invention is further drawn to non-peptide analogs that mimic the functions of the polypeptide disclosed herein, wherein these non-peptide analogs inhibit signaling mediated by TRAF6. Low molecular weight, non-peptide molecules that mimic the inhibitory polypeptides disclosed herein can serve as robust tools to help establish the role of TRAF6-mediated signaling in models of physiological and pathophysiological processes as well as serving as therapeutic agents in their own right. A number of reports have disclosed the rationale and strategy for the design of low molecular weight, non-peptide molecules that are amenable to high resolution analysis and rapid modification (40-42). The present invention is also drawn to a method of inhibiting Receptor Activator of NF-κB Ligand (RANKL)-induced osteoclast differentiation using these non-peptide analogs, wherein inhibition of interaction between the receptor activator of NF-κB and TRAF6 by said non-peptide analogs result in inhibition of RANKL-induced osteoclast differentiation. This method can be used to inhibit osteoclast differentiation induced by breast cancer cells.
- The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.
- The human embryonic kidney 293 cell line and the mouse macrophage cell line RAW264.7 were obtained from the American Type Culture Collection (Rockville, Md.). The 293 cells were cultured in MEM supplemented with 10% fetal bovine serum and antibiotics. RAW264.7 cells were cultured in DMEM-F12 supplemented with 10% fetal bovine serum and antibiotics. Monoclonal antibodies to phospho-ERK, p38, and JNK were purchased from New England Biolabs. Goat anti-rabbit IgG-conjugated horseradish peroxidase was purchased from BioRad Laboratories (Hercules, Calif.). Anti-JNK1 and anti-IκB were purchased from Santa Cruz Biotechnology (Santa Cruz, Calif.). Goat anti-mouse IgG-conjugated horseradish peroxidase was purchased from Transduction Laboratories (Lexington, Ky.). Protein A/G Sepharose beads was purchased from Pierce (Rockford, Ill.), and anti-FLAG was purchased from Sigma (St. Louis, Mo.). Staining for tartrate resistance acid phosphatase (TRAP) positive osteoclasts was performed essentially as described (30) or by using an acid phosphatase kit from Sigma.
- Expression plasmids encoding mouse FLAG-tagged TRAF5 and TRAF6 (31) were provided by H. Nakano (Juntendo University, Tokyo, Japan) and FLAG-tagged TRAF2 was provided by J. Ni (Human Genome Sciences, Inc.). Expression vectors and purification of GST-fusion proteins for GST, GST-receptor activator of NF-κB cytoplasmic domain, and GST-Jun (1-79) have been previously described (7, 8). The expression vector of full-length murine RANKL (also known as TNF-related activation-induced cytokine (TRANCE) (pcDNA3.1-TRANCE) was provided by Y. Choi (Rockefeller University, New York, N.Y.).
- To generate a bacterial expression vector for RANKL, specific 5′ and 3′ primers with HindIII and NotI sites, respectively, were used to amplify the DNA which encodes residues 157-316 of RANKL from the pcDNA3-TRANCE template. The PCR product was digested with HindIII/NotI and ligated in-frame with a HA-tag (N-terminal) and a histidine tag (C-terminal) into the expression vector pHB6 (Boerhinger Mannheim). Soluble RANKL was expressed and purified using Ni-agarose.
- 293 cells were plated at 0.6×106 cells/well on 6-well plates and transfected the next day as described (8). Total amount of plasmid DNA was kept constant by adding empty pCMVFLAG1 vector. Cells and the conditioned supernatants were harvested 24-36 h after transfection. Lysates were prepared as described (8). For western blot analysis, whole-cell lysates (15-30 μg) or proteins from GST-affinity precipitation were separated by 8.5% SDS-PAGE, electroblotted onto nitrocellulose membranes, and incubated with the indicated antibodies. The membranes were then developed using the enhanced chemiluminescence (ECL) system (Amersham, Chicago, Ill.).
- Primary bone marrow monocytes (BM) or RAW264.7 cells were cultured in 48-well dishes at a density of 1×105 cells/well or 2×103 cells/well, and then treated with the indicated factors at the beginning of the culture and during a medium change on day 3. Osteoclast formation was assessed by counting the total number of multi-nucleated (>3 nuclei), TRAP-positive cells present per well between day 7 and 10 (BM) or on day 5 (RAW264.7) (30).
- Equivalent amounts of GST or GST-RANK cytoplasmic domain (GST-RANKcd) fusion protein attached to 20 μl of glutathione agarose beads were mixed with lysates (50 μg) from 293 cells programmed to express the epitope-tagged TRAF protein and the indicated peptides in binding buffer (20 mM TRIS, pH 8, 150 mM NaCl, 1 mM DTT, 2 mM EDTA, and 0.1% NP-40) and allowed to rotate for 1 h at 4° C. The beads were collected by centrifugation, washed three times in binding buffer, and then washed once in low-salt buffer (20 mM TRIS, pH 8, 50 mM NaCl, and 1 mM DTT). Bound proteins were eluted with addition of SDS-sample buffer and boiled. The eluted proteins were subjected to 7.5% SDS-PAGE and western blot analysis was performed with anti-FLAG antibodies.
- Lysates were prepared from RAW cells stimulated with RANKL as indicated in the legends to the figures. Approximately 30 μg was then used for immunoprecipitation with indicated antibodies and protein A/G Sepharose beads for 1 h. Beads were collected by centrifugation, washed three times in lysis buffer, and then washed two times in low-salt buffer. JNK activity was analyzed using exogenous GST-Jun (1-79) as a substrate as previously described (8). Kinase activity was quantitated using a PhosphoImager and Imagequant Software (Molecular Dynamics, Sunnyvale, Calif.).
- Nuclear extracts were prepared from transfected cells essentially as described (34). Equivalent amounts of nuclear protein were used in an EMSA reaction with32P-labeled NF-κB oligonucleotide from HIV-LTR as described (34). NF-κB activation was quantitated using a PhosphoImager and Imagequant Software.
- A novel TRAF6 binding domain in RANK, which binds to only TRAF6 but not TRAF2 or TRAF5, has been identified previously (8). When transfected in 293 cells, this region of the receptor activator of NF-κB was sufficient for activation of NF-κB (8). Structure-based sequence alignment of TRAF6-binding sites in human and mouse CD40 and RANK led to the definition of a TRAF6-binding motif PxExx(Ar/Ac) (Ar for aromatic and Ac for acidic residues) (FIG. 1A). Careful examination of the RANK sequence indicates that there are three potential TRAF6-binding sites (FIG. 1A).
- TRAF6 is the only TRAF family member that participates in the signal transduction of both the TNF receptor superfamily and the interleukin-1 receptor (IL-1R)/Toll-like receptor (TLR) superfamily. The best-characterized TRAF6 signaling pathway for the IL-1R/TLR superfamily involves IRAK, an adapter kinase upstream of TRAF6. Upon receptor stimulation, IRAK becomes oligomerized and interacts with TRAF6 (43). It was found that full-length IRAK contains three potential TRAF6-binding sites (FIG. 1A). Two IRAK homologues, IRAK-2 and IRAK-M, also contain two and a single potential TRAF6-binding site, respectively (FIG. 1A). This is in keeping with the implicated role of IRAK-2 and IRAK-M in IL-1 signaling and the role of IRAK-2 in TLR4 signaling. In addition, it was found that the kinase RIP2, which can activate NF-κB and induce cell death, also contains a putative TRAF6-binding site (FIG. 1A). The presence of TRAF6-binding sites in these various molecules suggests that TRAF6 may play a role in mediating multiple signaling cascades.
- Delivery of peptides or proteins across cellular membranes can be achieved by covalent attachment of the peptide to molecules that can freely pass through the membrane (35). For example, the hydrophobic domain of Kaposi fibroblast growth factor signal sequence was attached to the nuclear localization signal from the p50 subunit of NF-κB to allow for translocation across the membrane (36). In the present invention, this hydrophobic sequence was attached to peptides derived from murine RANK, namely L-T6DP-1 which contains the known TRAF6 binding domain and L-T6DP-2 which contains a similar motif (FIG. 1B). In addition, both of these peptides were synthesized without the leader sequence, resulting in peptides that were not be able to transverse cellular membrane (FIG. 1B).
- The mouse macrophage cell line RAW264.7 express the receptor activator of NF-κB on their cell surface and when stimulated with the receptor activator of NF-κB ligand differentiate into multi-nucleated, tartrate resistant acid phosphatase (TRAP) positive osteoclasts after 4-5 days (FIG. 2A). To determine whether L-T6DP-1 could inhibit RANKL-mediated osteoclast differentiation, RAW264.7 cells were co-cultured with increasing concentrations of either L-T6DP-1. or T6DP-1 and 30 ng/ml RANKL for 4 days.
- As indicated in FIG. 2B, TRAF6decoy peptide without leader sequence failed to block RANKL-mediated osteoclast differentiation; however, treatment with L-T6DP-1 caused a dose-dependent inhibition of osteoclast differentiation. Although the cells were TRAP positive after treatment with 100 μM L-T6DP-1, multi-nucleated osteoclast were not observed (FIG. 2B). Furthermore, treatment of RAW264.7 cells with RANKL in the presence of either L-T6DP-1 or L-T6DP-2 caused a dose-dependent decrease of TRAP positive osteoclasts (FIG. 2C), although L-T6DP-1 was much more efficient than L-T6DP-2.
- To further support the results obtained from the RAW264.7 cell line, the ability of these peptides to inhibit RANKL-mediated osteoclast differentiation in primary mouse-derived monocytes was tested. Costimulation of bone marrow-derived monocytes with RANKL and M-CSF cause osteoclast differentiation after 7-10 days, as determined by staining multi-nucleated, TRAP positive osteoclasts (30). Similar to the results with RAW264.7 cells, both L-T6DP-1 and L-T6DP-2 inhibited the development of TRAP positive osteoclast in a dose-dependent manner and L-T6DP-1 was much more efficient (FIG. 3). TRAF6decoy peptides without the leader sequences failed to inhibit osteoclast differentiation (FIG. 3), indicating that the peptides were not toxic to the cells. Although the cells were TRAP positive after treatment with 30 μM L-T6DP-1, multi-nucleated osteoclast were not observed and at 100 μM L-T6DP-1, no osteoclasts were observed (FIG. 3B). Taken together, these results indicate that interaction of TRAF6 with RANK is essential for RANKL-mediated osteoclast differentiation.
- A mutant form of the receptor activator of NF-κB which contains only the TRAF6 binding domain is sufficient to activate NF-κB (8), and a dominant negative TRAF6 inhibits RANK-mediated NF-κB activation in 293 cells (9). To investigate the effect of the TRAF6 binding peptides on RANKL-induced NF-κB activation, NF-κB activation was examined in RAW264.7 cells that activated NF-κB when stimulated with RANKL (37). RANKL-stimulated RAW264.7 cells activated NF-κB as indicated by a gel mobility shift assay (FIG. 4A). NF-κB activation was suppressed in a dose-dependent manner only by pre-treatment with L-T6DP-1 (FIG. 4A). The levels of IκBα coincided with the activation and repression of NF-κB as indicated in FIG. 4B. These data indicate that L-T6DP-1 specifically inhibits RANKL-mediated NF-κB activation in RAW264.7 cells.
- The cytoplasmic domain of RANK interacts with many TRAF molecules, including TRAF1, 2, 3, 5, and 6 (7-9, 11, 12). While TRAF1, 2, 3, and 5 interact with the c-terminal tail of receptor activator of NF-κB, TRAF6 interacts with a membrane proximal region of the cytoplasmic domain of the receptor activator of NF-κB. To confirm that the TRAF6-binding peptides disclosed herein were specifically inhibiting TRAF6 interaction with RANK, a competitive GST-pull down assay was performed.
- Cellular extracts containing FLAG-tagged TRAF2, TRAF5, or TRAF6 were mixed with GST-RANK cytoplasmic domain fusion protein in the presence and absence of either L-T6DP-1 or L-T6DP-2. If these peptides competed for the TRAF molecules, less FLAG-tagged protein would be observed in the western blots. As shown in FIG. 4, neither L-T6DP-1 nor L-T6DP-2 inhibited TRAF2 and TRAF5 binding to the cytoplasmic domain of RANK (FIG. 4C). Only L-T6DP-1 inhibited TRAF6 interaction with the cytoplasmic domain of RANK (FIG. 4C). These data indicate that the leader sequence did not interfere with interaction of the receptor activator of NF-κB with TRAFs and that L-T6DP-1 specifically inhibited RANK's interaction with TRAF6.
- Stimulation of the receptor activator of NF-κB activates members of the MAPK family including JNK, ERK and p38 kinase. The ability of the TRAF6 binding peptides to inhibit the receptor activator of NF-κB ligand-induced JNK, ERK, and p38 kinase activation was examined in RAW264.7 cells. In vitro JNK kinase assays indicated JNK is activated by RANKL and only treatment with L-T6DP-1 peptide was capable of inhibiting RANKL-mediated JNK activation (FIG. 5A). Similar to the results with JNK, only L-T6DP-1 was able to block ERK (FIG. 5B) and p38 kinase (FIG. 5C) activation induced by the receptor activator of NF-κB ligand in RAW264.7 cells. Taken with the results disclosed above, the present invention demonstrates that L-T6DP-1 is able to suppress the receptor activator of NF-κB ligand-mediated osteoclast differentiation and the receptor activator of NF-κB ligand-initiated early signaling including NF-κB, JNK, ERK, and p38 kinase activation.
- Breast cancer is the most common female malignancy in the U.S. and is the second leading cause of cancer death in women. Women with breast cancer are at risk for bone metastases. Five to ten percent of patients with breast cancer initially present with metastatic disease to the bone. Patients with osteolytic bone disease from metastatic breast cancer are at increased risk for pathologic fractures, bone pain, cord compression and hypercalcemia. Current standard of care for treating bone metastases is bisphosphonate therapy which delays skeletal events but does not completely prevent them. In addition, not all patients respond to this treatment. While a more effective treatment is desired, a further biological and molecular dissection of this disease is required. In fact, recently it was demonstrated that osteoprotegerin (OPG) inhibits osteolysis and decreases tumor burden in nude mouse models injected with breast cancer cells.
- The ability of breast cancer cells to induce osteoclast formation and the expression of receptor activator of NF-κB/the receptor activator of NF-κB ligand/osteoprotegerin in breast cancer cells are not well defined. Few reports have demonstrated the ability of breast cancer cell lines to influence osteoclast differentiation and function; however, no evidence has been described for the direct involvement of the receptor activator of NF-κB ligand in this process. As indicated below, there is evidence to support the hypothesis that breast cancer cells directly induce osteoclast differentiation and function in the absence of osteoblast/stromal cells. Through the understanding of the biological and molecular role of the receptor activator of NF-κB ligand in breast cancer cells in the bone microenvironment and development of novel inhibitors of osteoclast formation as described herein, alternative therapeutic approaches or combination therapy may be developed to treat breast cancer patients with bone metastases.
- In the present example, a co-culture assay system was developed for RAW cells and the osteoblast-like cell (osteosarcoma MG-63) which has been shown to express the receptor activator of NF-κB ligand and cause osteoclast differentiation. The number of MG-63 cells was critical for inducing RAW cells to differentiate into osteoclasts. These observations lead to a direct inverse relationship between the number of RAW cells to MG-63 cells which is required for the formation of osteoclasts. Results using RAW cells co-cultured with MG-63 (data not shown) or with breast cancer cell lines (i.e., T47D and MDA-MB-468) indicated that these breast cancer cells could in fact cause RAW cells to form TRAP+, multi-nucleated osteoclasts after 4 days (FIG. 6A) similar to RAW cells stimulated with the receptor activator of NF-κB ligand. In addition, when the breast cancer cell lines were grown in tissue culture inserts where they were separated from RAW cells by a membrane, osteoclast still formed, suggesting that direct cell-to-cell contact was not required for osteoclast differentiation (data not shown). When grown on synthetic bone slides, the osteoclasts derived from the co-culture assays were able to cause bone resorption (FIG. 6B).
- When L-T6DP-1 was added to these co-culture assays, the ability of the breast cancer cells to induce osteoclast differentiation of RAW cells was abolished, whereas T6DP-1 had no effect (FIG. 6A). Normal breast epithelial cells, MCF-10A, failed to induce osteoclast differentiation of RAW; however, osteoclasts did form if exogenous the receptor activator of NF-κB ligand was added to these co-cultures (FIG. 6C). Collectively, these data indicate that breast cancer cell lines, but not normal breast epithelial cells, can directly induce osteoclast differentiation in the absence of osteoblast/stromal cells and that L-T6DP-1 can inhibit this process.
- An ELISA-based method similar to one described previously (J. Biol. Chem., 276:12235-12240, 2001) can be used to discover small molecules that inhibit RANK-TRAF6 interaction. Briefly, peptides comprising the T6DP are biotinylated, dissolved in TRIS-buffered saline (50 mM TRIS pH 7.5, 150 mM NaCl), and added to wells in NeutrAvidin-coated 96-well microtiter plates. The plates are shaken overnight at 4° C. and then rinsed with TBS followed by TBS-BT (TBS containing 0.1%bovine serum albumin (BSA) and 0.1% Tween 20). A solution containing a test small molecule from a library is then added to the well. A solution containing 6×-histidine-tagged TRAF6 (309-522) is then added to each well. The plates are 4incubated for 1 h at room temperature and then washed 3 times with TBS-BT. An antibody directed against the C-terminus of TRAF6 is then added to the wells and the plates are incubated for 1 hour a t room temperature, followed by 3 washes with TBS-BT. A secondary antibody consisting of goat anti-mouse alkaline phosphatase is then added to each well and the plates are incubated for 1 hour at room temperature, followed by 3 washes with TBS-BT. The plates are then assayed for alkaline phosphatase activity using a fluorescent plate reader as previously described (Darnay et al., J. Biol. Chem. 274:7724-7731, 1999).
- 1. Darnay and Aggarwal. 1999. Ann. Rheum. Dis. 58 Suppl 1:12.
- 2. Darnay and Aggarwal. 1997. J Leukoc. Biol. 61:559.
- 3. Wallach et al. 1999. Ann. Rev. Immunol. 17:331.
- 4. Hofbauer et al. 2000. J. Bone Miner. Res. 15:2.13
- 5. Kong et al. 1999. Nature 397:315.
- 6. Wong et al. 1997. J Exp. Med. 186:2075.
- 7. Darnay et al. 1998. J Biol. Chem. 273:20551.
- 8. Darnay et al. 1999. J Biol. Chem. 274:7724.
- 9. Galibert et al. 1998. J Biol. Chem. 273:34120.
- 10. Kim et al. 1999. FEBS Lett. 443:297.
- 11. Hsu et al. 1999. Proc. Natl. Acad. Sci. U S A 96:3540.
- 12. Wong et al. 1998. J Biol. Chem. 273:28355.
- 13. Pahl. 1999. Oncogene 18:6853.
- 14. Arch et al. 1998. Genes Dev. 12:2821.
- 15. McWhirter et al. 1999. Proc. Natl. Acad. Sci. U S A 96:8408.
- 16. Park et al. 1999. Nature 398:533.
- 17. Pullen et al. 1999. J Biol. Chem,. 274:14246.
- 18. Wong et al. 1999. Mol. Cell 4:1041.
- 19. Bucay et al. 1998. Genes Dev. 12:1260.
- 20. Mizuno et al. 1998. Biochem. Biophys. Res. Commun. 247:610.
- 21. Li et al. 2000. Proc. Natl. Acad. Sci. U S A 97:1566.
- 22. Dougall et al. 1999. Genes Dev. 13:2412.
- 23. Lomaga et al. 1999. Genes Dev. 13:1015.
- 24. Naito et al. 1999. Genes Cells 4:353.
- 25. Kobayashi et al. 2001. EMBO J 20:1271.
- 26. Soriano et al. 1991. Cell 64:693.
- 27. Johnson et al. 1992. Cell 71:577.
- 28. Iotsova et al. 1997. Nat. Med. 3:1285.
- 29. Franzoso et al. 1997. Genes Dev. 11:3482.
- 30. Shevde et al. 2000. Proc. Natl. Acad. Sci. USA 97:7829.
- 31. Akiba et al. 1998. J Biol. Chem. 273:13353.
- 32. Hu et al. 1996. Genes Dev. 10:2251.
- 33. Yao et al. 1999. J Biol. Chem. 274:2118.
- 34. Haridas et al. 1998. J Immunol. 160:3152.
- 35. Schwarze et al. 2000. Trends Cell Biol. 10:290.
- 36. Yan et al. 2000. J Biol. Chem. 275:16774.
- 37. Wei et al. 2001. Endocrinology 142:1290.
- 38. Ishida et al. 1996. J Biol. Chem. 271:28745.
- 39. Futaki et al. 2001. J Biol. Chem. 276:5836.
- 40. Horwell. 1995. Trends Biotechnol. 13:132.
- 41. Wexler et al. 1992. Am. J. Hypertens. 5:209S.
- 42. Saragovi et al. 1992. Biotechnology 10:773.
- 43. Wesche et al. 1999. J Biol. Chem. 274:19403.
- Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. Further, these patents and publications are incorporated by reference herein to the same extent as if each individual publication is specifically and individually indicated to b e incorporated by reference.
- One skilled in the art will appreciate readily that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and advantages inherent herein. The present examples, along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.
-
1 22 1 9 PRT Homo sapiens DOMAIN TRAF6 binding domain from human CD40 1 Lys Gln Glu Pro Gln Glu Ile Asn Phe 5 2 9 PRT Unknown DOMAIN TRAF6 binding domain from mouse CD40 2 Arg Gln Asp Pro Gln Glu Met Glu Asp 5 3 9 PRT Homo sapiens DOMAIN TRAF6 binding domain from human RANK 3 Arg Gln Met Pro Thr Glu Asp Glu Tyr 5 4 9 PRT Homo sapiens DOMAIN TRAF6 binding domain from human RANK 4 Phe Ser Glu Pro Leu Glu Val Gly Glu 5 5 9 PRT Homo sapiens DOMAIN TRAF6 binding domain from human RANK 5 Arg Asn Pro Pro Gly Glu Asp Cys Glu 5 6 9 PRT Unknown DOMAIN TRAF6 binding domain from mouse RANK 6 Arg Lys Ile Pro Thr Glu Asp Glu Tyr 5 7 9 PRT Unknown DOMAIN TRAF6 binding domain from mouse RANK 7 Phe Gln Glu Pro Leu Glu Val Gly Glu 5 8 9 PRT Unknown DOMAIN TRAF6 binding domain from mouse RANK 8 Gly Asn Thr Pro Gly Glu Asp His Glu 5 9 9 PRT Homo sapiens DOMAIN TRAF6 binding domain from human IRAK-1 9 Pro Pro Ser Pro Gln Glu Asn Ser Tyr 5 10 9 PRT Homo sapiens DOMAIN TRAF6 binding domain from human IRAK-1 10 Pro Asn Gln Pro Val Glu Ser Asp Glu 5 11 9 PRT Homo sapiens DOMAIN TRAF6 binding domain from human IRAK-1 11 Arg Gln Gly Pro Glu Glu Ser Asp Glu 5 12 9 PRT Unknown DOMAIN TRAF6 binding domain from mouse IRAK 12 Ser Pro Ser Pro Gln Glu Asn Ser Tyr 5 13 9 PRT Unknown DOMAIN TRAF6 binding domain from mouse IRAK 13 Pro Asn Gln Pro Val Glu Ser Asp Glu 5 14 9 PRT Unknown DOMAIN TRAF6 binding domain from mouse IRAK 14 Ser Gln Gly Pro Glu Glu Ser Asp Glu 5 15 9 PRT Homo sapiens DOMAIN TRAF6 binding domain from human IRAK-2 15 Ser Asn Thr Pro Glu Glu Thr Asp Asp 5 16 9 PRT Homo sapiens DOMAIN TRAF6 binding domain from human IRAK-2 16 Pro Leu Leu Pro Thr Glu Asn Gly Glu 5 17 9 PRT Homo sapiens DOMAIN TRAF6 binding domain from human IRAK-M 17 Pro Ser Ile Pro Val Glu Asp Asp Glu 5 18 9 PRT Homo sapiens DOMAIN TRAF6 binding domain from human RIP2 18 Ile Tyr Met Pro Pro Glu Asn Tyr Glu 5 19 34 PRT Unknown PEPTIDE Peptide L-T6Bp-1 19 Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala 5 10 15 Pro Arg Lys Ile Pro Thr Glu Asp Glu Tyr Thr Asp Arg Pro Ser 20 25 30 Gln Pro Ser Thr 20 30 PRT Unknown PEPTIDE Peptide L-T6Bp-2 20 Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala 5 10 15 Pro Ile Pro Pro Phe Gln Glu Pro Leu Glu Val Gly Glu Asn Asp 20 25 30 21 19 PRT Unknown PEPTIDE Peptide T6Bp-1 21 Cys Arg Lys Ile Pro Thr Glu Asp Glu Tyr Thr Asp Arg Pro Ser 5 10 15 Gln Pro Ser Thr 22 15 PRT Unknown PEPTIDE Peptide T6Bp-2 22 Cys Ile Pro Pro Phe Gln Glu Pro Leu Glu Val Gly Glu Asn Asp 5 10 15
Claims (25)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/143,293 US6998383B2 (en) | 2001-05-11 | 2002-05-10 | Inhibitors of receptor activator of NF-κB and uses thereof |
US10/786,316 US20040167072A1 (en) | 2001-05-11 | 2004-02-25 | Inhibitors of receptor activator of NF-kappaB and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29042901P | 2001-05-11 | 2001-05-11 | |
US10/143,293 US6998383B2 (en) | 2001-05-11 | 2002-05-10 | Inhibitors of receptor activator of NF-κB and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/786,316 Continuation-In-Part US20040167072A1 (en) | 2001-05-11 | 2004-02-25 | Inhibitors of receptor activator of NF-kappaB and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
US20030013170A1 true US20030013170A1 (en) | 2003-01-16 |
US6998383B2 US6998383B2 (en) | 2006-02-14 |
Family
ID=23115949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/143,293 Expired - Fee Related US6998383B2 (en) | 2001-05-11 | 2002-05-10 | Inhibitors of receptor activator of NF-κB and uses thereof |
Country Status (7)
Country | Link |
---|---|
US (1) | US6998383B2 (en) |
EP (1) | EP1385872A4 (en) |
JP (1) | JP4603240B2 (en) |
AU (1) | AU2002256518B2 (en) |
CA (1) | CA2447431A1 (en) |
NZ (1) | NZ529314A (en) |
WO (1) | WO2002092623A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040167072A1 (en) * | 2001-05-11 | 2004-08-26 | Aggarwal Bharat B. | Inhibitors of receptor activator of NF-kappaB and uses thereof |
US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
US6884598B2 (en) | 2000-09-22 | 2005-04-26 | Immunex Corporation | Screening assays for agonists and antagonists of receptor activator of NF-κB |
US20120077749A1 (en) * | 2008-04-17 | 2012-03-29 | Baxter Healthcare S.A. | Biologically Active Peptides |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1496880A4 (en) * | 2002-04-24 | 2007-12-12 | Res Dev Foundation | SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-kB INHIBITORS AND ANTI-NEOPLASTIC AGENTS |
WO2004000229A2 (en) * | 2002-06-24 | 2003-12-31 | Research Development Foundation | Treatment of human multiple myeloma by curcumin |
JP2007503475A (en) * | 2003-08-26 | 2007-02-22 | リサーチ ディベロップメント ファウンデーション | Osteoclast formation inhibitor and method of use thereof |
CN103211821A (en) | 2006-04-22 | 2013-07-24 | 霍利斯—伊登医药公司 | Drugs and uses |
WO2008044824A1 (en) * | 2006-10-13 | 2008-04-17 | Seoul National University Industry Foundation | Antibodies to ip-10 for treating bone diseases with bone destruction |
PL2205623T3 (en) * | 2007-10-29 | 2016-09-30 | Protective skin care tetrapeptides | |
WO2010141845A2 (en) | 2009-06-05 | 2010-12-09 | 13Therapeutics, Inc. | Immunoregulatory peptides and methods of use |
KR101180431B1 (en) * | 2010-05-27 | 2012-09-06 | 성균관대학교산학협력단 | Peptide Inhibiting RANKL-RANK Interaction and Pharmaceutical Composition Comprising the Same |
WO2012138879A2 (en) | 2011-04-06 | 2012-10-11 | 13Therapeutics, Inc. | Peptides for the treatment of hearing |
WO2014178078A2 (en) | 2013-04-30 | 2014-11-06 | Intas Boipharmaceuticals Limited | Novel cloning, expression & purification method for the preparation of ranibizumab |
KR20150050646A (en) * | 2013-10-29 | 2015-05-11 | 삼성전자주식회사 | Fusion peptide and use thereof for cell membrane penetrating |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
US6017729A (en) * | 1996-12-23 | 2000-01-25 | Immunex Corporation | Receptor activator of NF-κB |
US6271349B1 (en) * | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
US20040167072A1 (en) * | 2001-05-11 | 2004-08-26 | Aggarwal Bharat B. | Inhibitors of receptor activator of NF-kappaB and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2009025B1 (en) | 1998-05-14 | 2011-07-27 | Immunex Corporation | Method of inhibiting osteoclast activity |
US6610820B1 (en) * | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
-
2002
- 2002-05-10 CA CA002447431A patent/CA2447431A1/en not_active Abandoned
- 2002-05-10 JP JP2002589506A patent/JP4603240B2/en not_active Expired - Fee Related
- 2002-05-10 WO PCT/US2002/014842 patent/WO2002092623A1/en active IP Right Grant
- 2002-05-10 EP EP02725988A patent/EP1385872A4/en not_active Withdrawn
- 2002-05-10 NZ NZ529314A patent/NZ529314A/en unknown
- 2002-05-10 AU AU2002256518A patent/AU2002256518B2/en not_active Ceased
- 2002-05-10 US US10/143,293 patent/US6998383B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6017729A (en) * | 1996-12-23 | 2000-01-25 | Immunex Corporation | Receptor activator of NF-κB |
US6271349B1 (en) * | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
US20040167072A1 (en) * | 2001-05-11 | 2004-08-26 | Aggarwal Bharat B. | Inhibitors of receptor activator of NF-kappaB and uses thereof |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6884598B2 (en) | 2000-09-22 | 2005-04-26 | Immunex Corporation | Screening assays for agonists and antagonists of receptor activator of NF-κB |
US20050196801A1 (en) * | 2000-09-22 | 2005-09-08 | Immunex Corporation | Screening assays for agonists or antagonists or receptor activator of NF-kappaB |
US7572594B2 (en) | 2000-09-22 | 2009-08-11 | Immunex Corporation | Screening assays for agonists or antagonists or receptor activator of NF-κB |
US20040167072A1 (en) * | 2001-05-11 | 2004-08-26 | Aggarwal Bharat B. | Inhibitors of receptor activator of NF-kappaB and uses thereof |
US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
US20120077749A1 (en) * | 2008-04-17 | 2012-03-29 | Baxter Healthcare S.A. | Biologically Active Peptides |
US8822638B2 (en) * | 2008-04-17 | 2014-09-02 | Baxter International Inc. | Procoagulant peptides |
US9206234B2 (en) | 2008-04-17 | 2015-12-08 | Baxalta Incorporated | Biologically active peptides |
US9598464B2 (en) | 2008-04-17 | 2017-03-21 | Baxalta Incorporated | Biologically active peptides |
US10287319B2 (en) | 2008-04-17 | 2019-05-14 | Baxalta Incorporated | Biologically active peptides |
US10822376B2 (en) | 2008-04-17 | 2020-11-03 | Baxalta GmbH | Biologically active peptides |
Also Published As
Publication number | Publication date |
---|---|
JP4603240B2 (en) | 2010-12-22 |
WO2002092623A1 (en) | 2002-11-21 |
JP2005503349A (en) | 2005-02-03 |
WO2002092623A8 (en) | 2004-01-08 |
NZ529314A (en) | 2007-01-26 |
EP1385872A4 (en) | 2004-12-15 |
CA2447431A1 (en) | 2002-11-21 |
US6998383B2 (en) | 2006-02-14 |
EP1385872A1 (en) | 2004-02-04 |
AU2002256518B2 (en) | 2007-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6998383B2 (en) | Inhibitors of receptor activator of NF-κB and uses thereof | |
US6831065B2 (en) | Anti-inflammatory compounds and uses thereof | |
US5563039A (en) | TNF receptor-associated intracellular signaling proteins and methods of use | |
AU732793B2 (en) | Modulators of TNF receptor associated factor (TRAF), their preparation and use | |
AU2002256518A1 (en) | Inhibitors of receptor activator of NF-kappaB and uses thereof | |
US8242240B2 (en) | Anti-inflammatory compounds and uses thereof | |
AU8283798A (en) | Ikk-beta proteins, nucleic acids and methods | |
WO2001068666A1 (en) | Tcl1 enhances akt kinase activity and mediates its nuclear translocation | |
KR100565819B1 (en) | Compounds that inhibit interaction between signal-transducing proteins and the glgfpdz/dhr domain and uses thereof | |
US20040167072A1 (en) | Inhibitors of receptor activator of NF-kappaB and uses thereof | |
CA2172490A1 (en) | Receptor recognition factors, protein sequences and methods of use thereof | |
US20040109854A1 (en) | Novel traf6 inhibiting protein | |
AU767967B2 (en) | Modulators of TNF receptor associated factor (TRAF), their preparation and use | |
AU2007202315B2 (en) | Anti-inflammatory compounds and uses thereof | |
Summy | Functional domain contributions to signaling specificity between the non-receptor tyrosine kinases c-Src and c-Yes | |
Turner | Signal transduction by the high affinity receptor for immunoglobulin E, FcϵRI, in the mast cell line RBL-2H3 | |
Turner | Signal transduction by the high affinity receptor for immunoglobulin E, FcepsilonRI, in the mast cell line RBL-2H3 | |
IL126428A (en) | Modulators of tnf receptor associated factor (traf), their preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: RESEARCH DEVELOPMENT FOUNDATION, NEVADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AGGARWAL, BHARAT;DARNAY, BRYANT G.;SINGH, SUJAY;REEL/FRAME:013050/0310;SIGNING DATES FROM 20020606 TO 20020610 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20140214 |